Unicycive Therapeutics, Inc. (UNCY) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 28, 2025, by Unicycive Therapeutics, Inc., a Delaware corporation trading on the Nasdaq Capital Market. The filing addresses preliminary financial results for the quarter ended September 30, 2025, and provides an update on regulatory proceedings regarding its New Drug Application (NDA) for Oxylanthanum Carbonate.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $42 million as of September 30, 2025 (preliminary, unaudited).
- Revenue, Profit, and Margins: The filing text does not provide clear values for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: Specific debt figures are not disclosed; liquidity is indicated solely by the preliminary cash balance.
Material Changes and Operational Updates
The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on June 30, 2025, regarding its NDA for Oxylanthanum Carbonate. On October 28, 2025, the Company announced an update following a meeting with the FDA, including the timing for the resubmission of the NDA. No specific financial variances versus prior periods are detailed in this filing.
Guidance, Risks, and Contingencies
The financial data presented is preliminary and unaudited. The Company's independent registered public accounting firm has not reviewed these figures. Complete quarterly results will be reported in the Form 10-Q for the quarter ended September 30, 2025. The primary contingency involves the successful resubmission and approval of the NDA for Oxylanthanum Carbonate following the FDA's Complete Response Letter.
Investor Verification Checklist
- Verify the final audited cash balance and full financial statements in the upcoming Form 10-Q.
- Confirm the specific timeline for the NDA resubmission for Oxylanthanum Carbonate as detailed in the press release (Exhibit 99.1).
- Monitor the Company's cash burn rate given the preliminary cash position of $42 million.
- Review the full text of the FDA Complete Response Letter to understand the specific deficiencies addressed in the resubmission plan.